Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

Epidermal growth factor receptor vIII (EGFRvIII) is a tumor-specific, ligand-independent, constitutively active variant of the EGFR. Its expression has been detected in gliomas and various other human malignancies. To more fully characterize the function and potential biological role of EGFRvIII in regulating cell proliferation and in tumorigenesis, we transfected EGFRvIII cDNA into a nontumorigenic, interleukin 3 (IL-3)-dependent murine hematopoietic cell line (32D cells). We observed 32D cells expressing high levels of EGFRvIII (32D/EGFRvIII P5) to be capable of abrogating the IL-3-dependent pathway in the absence of ligands. In contrast, the parental cells, 32D/EGFR, 32D/ErbB-4, and 32D/ErbB-2+ErbB-3 cells, all depended on IL-3 or EGF-like ligands for growth. 32D/EGFRvIII P5 cells subjected to long-term culture conditions in the absence of IL-3 revealed further elevation of EGFRvIII expression levels. These results suggested that the IL-3-independent phenotype is mediated by EGFRvIII. The level of expression is a critical driving force for the IL-3-independent phenotype. Dose-response analysis revealed 32D/EGFRvIII cells to require 500-fold higher concentrations (50 ng/ml) of EGF to further stimulate the EGF-mediated proliferation than in the 32D/EGFR cells (100 pg/ml). Similar effects were also observed in beta-cellulin-mediated proliferation. Moreover, 32D cells expressing high levels of EGFRvIII formed large tumors in nude mice, even when no exogenous EGF ligand was administered. In contrast, no tumors grew in mice injected with 32D/EGFR, 32D/ErbB-4, and 32D/ErbB-2+ErbB-3 cells or low-expressing clone 32D/EGFRvIII C2 cells or the parental 32D cells. The changes of the ligand specificity support the notion for an altered conformation of EGFRvIII to reveal an activated ligand-independent oncoprotein with tumorigenic activity analogous to v-erbB. These studies clearly demonstrate that EGFRvIII is capable of transforming a nontumorigenic, IL-3-dependent murine hematopoietic cell line (32D cells) into an IL-3-independent and ligand-independent malignant phenotype in vitro and in vivo. To delineate the biological significance of EGFRvIII in human breast cancer, we expressed EGFRvIII in the MCF-7 human breast cancer cell line. Expression of EGFRvIII in MCF-7 cells produced a constitutively activated EGFRvIII receptor. Expression of EGFRvIII in MCF-7 cells also elevated ErbB-2 phosphorylation, presumably through heterodimerization and cross-talk. These MCF-7/EGFRvIII transfectants exhibited an approximately 3-fold increase in colony formation in 1% serum with no significant effect observed at higher percentages of serum. A similar result was also seen in anchorage-dependent assays. Furthermore, EGFRvIII expression significantly enhanced tumorigenicity of MCF-7 cells in athymic nude mice with P < 0.001. Collectively, these results provide the first evidence that EGFRvIII could play a pivotal role in human breast cancer progression.

[1]  P. Fedi,et al.  Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors , 1997, The EMBO journal.

[2]  D. Bigner,et al.  Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). , 1997, The Biochemical journal.

[3]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[4]  R. B. Montgomery,et al.  Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. , 1996, Oncogene.

[5]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[6]  T. van Raaij,et al.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.

[7]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[8]  P. Humphrey,et al.  Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[9]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[10]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[11]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[12]  V. P. Collins,et al.  Altered subcellular location of an activated and tumour-associated epidermal growth factor receptor. , 1995, Oncogene.

[13]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[14]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. P. Collins,et al.  Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. , 1994, Oncogene.

[16]  A. Burgess,et al.  Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .

[17]  H. Kung,et al.  Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor. , 1994, Critical reviews in oncogenesis.

[18]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[19]  H. Kawasaki,et al.  A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. , 1993, The Journal of biological chemistry.

[20]  C. James,et al.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Pierce.  Signal Transduction Through Foreign Growth Factor Receptors and Oncogenes Transfected into Interleukin-3-Dependent Hematopoietic Cells , 1992 .

[23]  A. Harris,et al.  Epidermal growth factor receptor and other oncogenes as prognostic markers. , 1992, Journal of the National Cancer Institute. Monographs.

[24]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[25]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Shibuya,et al.  A Deletion Mutation within the Ligand Binding Domain Is Responsible for Activation of Epidermal Growth Factor Receptor Gene in Human Brain Tumors , 1990, Japanese journal of cancer research : Gann.

[27]  T. Fleming,et al.  Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. , 1989, Oncogene.

[28]  P. Humphrey,et al.  Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.

[29]  M. Shibuya,et al.  Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.

[30]  J. Schlessinger,et al.  Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. , 1988, Science.

[31]  A. Ullrich,et al.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.

[32]  I. Pastan,et al.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. , 1987, Science.

[33]  D. Neal,et al.  Evaluation of epidermal growth factor receptors in bladder tumours. , 1987, British Journal of Cancer.

[34]  B. Gusterson,et al.  Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomas , 1986, The Journal of pathology.

[35]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[36]  H. Ogawara,et al.  Purification of the epidermal growth factor receptor by tyrosine-Sepharose affinity chromatography. , 1985, Biochemical and biophysical research communications.

[37]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.